Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ: HRMY · Real-Time Price · USD
32.90
-0.07 (-0.21%)
At close: Jun 16, 2025, 4:00 PM
32.95
+0.05 (0.15%)
After-hours: Jun 16, 2025, 7:57 PM EDT
-0.21%
Market Cap 1.89B
Revenue (ttm) 744.85M
Net Income (ttm) 152.72M
Shares Out 57.42M
EPS (ttm) 2.62
PE Ratio 12.55
Forward PE 10.28
Dividend n/a
Ex-Dividend Date n/a
Volume 635,137
Open 33.16
Previous Close 32.97
Day's Range 32.67 - 33.42
52-Week Range 26.47 - 41.61
Beta 0.87
Analysts Strong Buy
Price Target 54.22 (+64.8%)
Earnings Date Aug 5, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 19, 2020
Employees 268
Stock Exchange NASDAQ
Ticker Symbol HRMY
Full Company Profile

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price forecast is $54.22, which is an increase of 64.80% from the latest price.

Price Target
$54.22
(64.80% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational,...

5 days ago - Business Wire

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation relat...

11 days ago - Business Wire

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th ...

12 days ago - Business Wire

Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executi...

5 weeks ago - Seeking Alpha

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

​PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way ...

5 weeks ago - Business Wire

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the o...

6 weeks ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evalu...

2 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President...

2 months ago - Business Wire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

2 months ago - Accesswire

Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

2 months ago - Accesswire

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annua...

2 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Harmony Biosciences Holdings, Inc. (HRMY) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

2 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Reach Out

NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the ...

3 months ago - Accesswire

Harmony Biosciences: A Compelling Risk-Reward Opportunity

Harmony Biosciences offers a promising investment with one commercial drug, WAKIX, and a robust pipeline, despite some setbacks and risks. The company's financial health is strong, with significant ca...

3 months ago - Seeking Alpha

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO)...

3 months ago - Business Wire

HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm.

3 months ago - Business Wire